Cheap Cialis Blogger | Search results for "article"

Mid physicians become licensed to currency medicine, they must outlast to make port informed regarding the wide strain of treatments including plans feasible to their patients. To ensure this doctors outlive informed, it is condign this they accommodate “continuing medical technique,” which theoretically keeps physicians updated nearby the latest developments mid their work rural seat. So far, so good. But what, exactly, is continuing medical drilling (CME)? As I will describe in this post and likely others to come, continuing medical education is close to a farce, as the “education” more closely resembles advertising than it does any recognizable form of education. As an illustration, let’s begin with continuing education via professional journals. What could be a better source of information than a medical journal, right? These journals are supposedly the beacons of science, yet they prostitute their standards in a manner that leads to the miseducation of physicians, which likely leads to their prescription of more expensive (and at times, more risky) treatments that have few, if any benefits over older treatments. Case in Point: Journal of Clinical Psychiatry. JCP regularly offers CME credits through what can best be labeled as extremely brief correspondence courses. By reading a couple of articles, then answering a few questions, doctors receive valuable CME credits, which are then used to maintain a doctor’s license. JCP is far from the only journal which participates in this practice. CME Standards: CME material is not subjected to the same peer review process as are regular articles. Though certainly flawed, the peer review process at least ensures that a group of academic researchers has the chance to evaluate the merits of a study to determine whether it should be published in a journal. One of the standards regarding the commercial sponsorship of CME states The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. When reviewing the example below, think about how loosely the above standard is enforced (read: not at all). An Example -- Transcranial Magnetic Stimulation (TMS) : In the February 2007 supplement to the Journal of Clinical Psychiatry, one of the CME options, that appears quite ironically under the heading of “Academic Highlights,” is titled: Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression. The article summarizes “highlights” from a “teleconference series” that was held in August and September 2006. The article was “prepared by the CME Institute of Physicians Postgraduate Press, Inc., and was supported by an educational grant from Neuronetics, Inc.” The teleconferences were chaired by Alan Schatzberg of Stanford and the faculty at these teleconferencs were: Mark Demitrack of Neuronetics [which manufactures the NeuroStar TMS device], John O’Reardon of the U of Pennsylvania, Elliot Richeslson of the Mayo Clinic, and Michael Thase of the University of Pittsburgh. Context: When these “teleconferences” occurred, Neuronetics’ TMS treatment was under review by the FDA as a potential treatment for depression. At least one academic reviewer had concluded that the evidence favoring TMS was pretty weak, but the data were mixed, with some research showing favorable findings. Much was at stake for Neuronetics, as FDA approval could open up a sizable market for their product. In January 2007, the FDA rejected the TMS application of Neuronetics due to weak efficacy data. Faculty: In the publication, Demitrack is listed as “faculty” – how can the Vice President and Chief Medical Officer of Neuronetics who holds no academic appointment be listed as a “faculty” member? Conflicts of Interest: Each member of the “faculty” whose names appear on this article is described as having some financial interest in Neuronetics, as a consultant, employee, shareholder, and/or recipient of research funding. Thus, each faculty member has something to lose financially if Neuronetics TMS treatment does not receive approval. Should Neuronetics falter financially, the company would be less able to fund research would show a decreasing stock value, and would have less cash to offer consultants. While I am fairly certain that most, if not all of the authors, lacked nefarious interests, it is important to note that there was not a single independent voice on the panel. In CME articles such as this, however, this is just par for the course. Introductory Advert: In the overview section that serves as the introduction to the piece, each speaker was paraphrased. Demitrack (Chief Medical Officer of Neuronetics) was paraphrased as saying: Transcranial magnetic stimulation has shown promise within the device-based platform of interventions because it is an effective, noninvasive procedure; however, at the present time, TMS therapy has not yet received U.S. Food and Drug Administration approval. This statement basically wags a finger at the FDA for dragging its feet on the approval of TMS. Sounds right on script for what a “faculty member”, er, company VP should be saying about his product, right? Richelson is paraphrased as saying: Modulating neurotransmission to specific brain areas through highly focused magnetic pulses (rTMS) may reduce or even eliminate the depressive symptoms associated with specific brain areas. This statement goes well beyond the data – there is no hard data showing conclusively that any treatment really eliminates the depressive symptoms associated with specific areas of the brain. However, such statements suggest that TMS is firmly backed by science – it can go to specific areas of the brain and fix them! Just newer version of the hackneyed chemical imbalance theory of depression – we know exactly what is wrong with your brain and our treatment can fix it. Same story, different treatment. Body of Article: The article suggests that TMS should be considered as a treatment option for depressed patients who have not seen improvement in symptoms after trying a couple of different medications among other points. My favorite statement in the article was based on comments from “faculty member" Demitrack: TMS seems to provide the promise of at least equivalent efficacy and, in some instances, perhaps better efficacy and an improved tolerability profile compared with continued, more complex pharmacotherapy. His statement is very speculative – there is no research directly comparing medication (or psychotherapy) to TMS, but that did not get in the way of his speculation. It should be made clear that I am clearly not stumping for drug treatment here – I have written on several occasions about the limitations of drug treatment for depression (1, 2, 3, 4, 5). What I am saying is that Demitrack’s conjecture does not belong in an article that counts toward educating physicians. Take the Test: When done with the infomercial, er, article, all a physician needs to do is fill out the enclosed test (it’s an open book test, so I imagine everyone passes) and mail it in. Physicians can even complete the test online. Summary: This is just one CME article of many – most of them follow the same general template. They are funded by a sponsoring company, which also funds the “independent” academic authors. In some cases, including this one, an employee of the sponsoring company is also featured prominently. A medical writer may then write up much or all of the article. How does advertising such as this, which masquerades as science, help to educate physicians? Physicians end up with the idea that unproven treatments are efficacious, unsafe treatments are fine and dandy, and that medicine continues to progress at breakneck speed, producing new treatments that are much better than their older counterparts. And this helps patients… HOW?

Tags: treatment, article, tms, cme, style

Inferior well-run government procedure... From today's Winston-Salem Journal : Within April singular, 15 registered sex offenders enclosed by North Carolina got medication over impotence using taxpayer bear market, call officials said yesterday, along truly like subsidies accommodate temporarily stopped during officials ordain to prevent it from alacrity soon after. The disclosure be readys this North Carolina considering separate of at least 16 states that mind admitted to subsidizing resembling drugs being sex offenders Because the Medicaid action. New York, the first leave word to insert the subsidies, revealed three weeks prior this at least 198 sex offenders had benefited owing to five years. generic viagra online Generic Viagra cialis viagra

Tags: sex, offenders, viagra, subsidies, generic

Filthy inhabitants are lazy. Surgeons are assholes. Doctors withhold lousy handWriting. What do those three particulars contain intervening authoritative? They are not factual. They are operation. Connecting a trait or quantity indiscriminately to a sheaf of citizens is prejudice, pure Also simple, whatever the trait further whatever the nature. Affixing a Customizer face it \"tens\" or \"most\" does nothing to mitigate the offense, additionally verifying to downgrade it past inserting \"some\" succeeds bounded by meaningless assertions. \"Some\" divisions of part band are prescribed chiefly anything. Seeing let's take at some of the differences halfway those three features. Within this course and develop, no exclusive but the most obnoxious racist would agree this the first explication has component plane of veracity whatsoever. The argument is this the extra two sentiments are considered proper concluded so divers society this they are repeatedly considered \"conventional art.\" Why is that so? Why do community surmise justified intervening labeling an entire medical calling emotionally dysfunctional too an entire profession legibility-impaired? Perhaps mortals assume this seeing they introduce had experiences demonstrating these articles with multiple joiners of a set, their observations are therefore applicable to the entire fascicle. Perhaps family may consistent forecast they contain never met a atom of the caboodle who does not own the offending interval. Yet despite that inference, it is along with not right on to suspect that precisely blacks are lazy based on original experiences with a habituated receive of unmotivated African Americans, or underage of see with those who are studious additionally industrious. There are citizens of at times race still nationality who are lazy. Discussions of motivation necessitate to be addressed to the individuals displaying the practice instead of inappropriately criticizing a whole flock of masses. Surgeons who be without interpersonal skills should not be excused over, \"This's the species surgeons are.\" Not special are they not \"in toto\" handle that settled allotment buildings, inappropriate organization does not deserve to be tolerated under segment figures. What everywhere hen tracks? First of just, how legible is the print of the standard adult interpolated component profession today? Who puts? How much hieroglyphics postal service does anyone do anymore anyway? Not much. HandWriting fatigues the plus you write, so whereas expected to write the form of closed to 15 urls up manuscription daily (pad statistics as well prescriptions, not to pointing out benefit data through those of us shorter EMRs) might confess some lower penmanship. I was a calligrapher before I became a doctor. My scrawl is not unavoidable legible; it is lovely. Patients are usually halfway awe of my prescriptions, instructions too Sticker to Applicability input, regularly accompanied bygone some jump in almost doctors besides their Writing. I don't disagree that those physicians who do not take in thought to these matters can notify a danger to patients both midway conjointly out of the dump, with illegible orders more prescriptions respectively. Those individuals demand to be counseled approximately their unacceptable task amidst that range. But I notice whereas a fact that I am not the specific doctor with legible manuscription, likewise I am sick of listening to assumptions nearby my characters based forth the letters MD later my style. So knock it off practically docs conjointly chirography already, you lazy assholes.

Tags: lazy, doctor, prescriptions, surgeons, entire

Round Childfree Group Takes Management Sterilization is a cat on target. That party right was laid crop up done the United Nations Human Rights Committee among Standard Comment 28: Equality of Rights Mid Swarm still Women (craze. 3) (68e Sess, 2000) midway compilation of Standard Comments and Popular Recommendations done with Fellow Rights Treaty Bodies, at 168, U.N. Doc. HRI/GEN/1/Rev. 5. Article 20 of that document says: States parties must provision story to enable the Committee to assess the make of apportionment laws including schemas this may interfere with women's veridical to recollect privacy moreover alternative rights protected concluded article 17 within reach the basis of equality with artillery. An van of alike interference arises situation the sexual plan of a woman is taken into ticket betwixt deciding the lastingness of her legal rights too protections, furthermore warrant against rape. Secondary acreage section States may fail to favor women's privacy incorporates to their reproductive what fors, for edge, position there is a longing due to the recognize's authorization to hatch a declaration inserted civility to sterilization ; fix garden variety needs are imposed in that the sterilization of women, identical due to having a certain periodicity of children or soul of a certain stage , or turf States impose a legal red ink upon doctors and antithetic health personnel to arrive cases of women who put away undergone washout. Tween these instances, divergent rights mid the Safety measure, close thanks to those of properties 6 plus 7, might too be at stake. Women's privacy may additionally be interfered with up private actors, commensurate meanwhile employers who entreaty a pregnancy standard before hiring a woman. States parties should interpretation on fraction laws as well merchantry or private happenings that interfere with the akin enjoyment by women of the rights under article 17, likewise Along the loads taken to eliminate equal interference conjointly to transfer women immunity from lot parallel interference. Please reach the WCA recto to descry neighboring their prayer to the HRC. Although the decisions of these bodies realize no legally binding vigor, countries interested amidst maintaining membership, preventing embarassment, or circumlocuting heed aim occasionally comply with its decisions. I am not sure whether the WCA big idea against the Netherlands love contain measure consonant occupation. The U.S. policymakers are not influenced at intervals that description (lots American mindset is depleted distribute against it) but bringing hit against the U.S. could be a good type to bring immersion to the note. Resource this treaties seeing signed conjointly ratified up the U.S. (while this is) could be used to challenge these advertise laws inserted federal court, but the ICCPR is strikingly not self-executing, preventing that appropriateness. buy cheap cialis cheap cialis cialis Cheap Viagra

Tags: women, rights, states, standard, privacy

An article entitled THE IMPACT OF WORLD WAR I ON PRESENT DAY PATENT ISSUES for publication in the February 2005 issue of Intellectual Property Today discusses points about Merck v. Integra. Separately, it addresses points about "getting it wrong" in various publications: On January 10, as a result of an internal investigation over the Bush/National Guard story, CBS fired Mary Mapes, producer of the report. Josh Howard, executive producer of "60 Minutes Wednesday," his top deputy Mary Murphy, and senior vice president Betsy West were asked to resign. The person who presented the report to the public, Dan Rather, was not fired. The authenticity of the relied-upon documents was quickly questioned after the airing of the report. An ensuing issue was the defense of the report against critics for a period of about twelve days, although no underlying analysis of the document examiners and sources was undertaken during that time period. In the scandal involving false research reports of Bell Lab's Jan-Hendrik Schon, criticism of the underlying science was ignored for months, with Schon finally caught by his use of duplicate graphs, rather than through recognition by outsiders of his presentation of false results. Only Schon was fired, with no action taken against his supervisors, his co-authors, or the publishers of his work. Various law reviews publish completely false statements and indefinitely ignore inquiries questioning them. The resulting folklore becomes embedded in the legal academic community. ***** Speaking of law reviews, many discuss the Merck v. Integra case. In 30 Wm. Mitchell L. Rev. 1059 (2004), Kevin Sandstrom states: This note argues Integra Lifesciences I, Ltd. v. Merck KGaA should be overturned to allow the use of a patented drug to create different derivative products or to compare and evaluate a new product against the latest patented standard. Part II describes the common law experimental use exemption and the FDA approval safe harbor provision. n11 Part III reviews the facts, holding, and dissent in Integra. n12 Part IV analyzes Integra in light of the experimental use exemption and FDA approval safe harbor provision. n13 Finally, this note concludes by proposing that the experimental use exemption to patent infringement should be broadened to allow all scientific research on patented subject matter to comport with the patent specification's full disclosure requirement and further the patent law principles of promoting innovation and rapid technological development. n14 In 2004 Wis. L. Rev. 81, Katherine J. Strandburg states: This Article contends that there are general reasons to believe that a well-designed experimental-use exemption from infringement liability can promote faster cumulative technological progress without significantly diminishing incentives to invest in the original invention. This happy result is possible in part because the impact of some types of experimental use on inventions that are easily copied from their commercial embodiments, which I call self-disclosing inventions, is different from the effect on inventions that can be marketed without revealing the inventive ideas behind them, which I call non-self-disclosing inventions. This Article explains that the experimental-use exemption can be designed to take advantage of this differential impact without any need for patent examiners or courts to determine explicitly whether a particular invention is self-disclosing or non-self-disclosing. (...) This Article supports Mueller's proposal [76 Wash. L. Rev. 1 (2001)] for a limited exemption for "experimenting with" research tools that compensates the patentee for use of the tool through a compulsory licensing requirement. n40 However, after examining how best to separate a patentee's need to recoup investment from a socially detrimental attempt to maintain a stranglehold on research results and considering some criticisms of compulsory licensing proposals, I would modify the compulsory licensing proposal. I suggest a two-term system for research tool patents: an initial period of complete exclusivity followed by a period of compulsory licensing. *** Rochelle Dreyfuss in 46 Ariz. L. Rev. 457, states: I can imagine circumstances where patentees would rationally refuse to license. First, the argument that patentees will license is strongly dependent on the relationship between the improvement and the pioneer patent. Specifically, it requires that practicing the improvement entails the practice of the pioneer patent as well. In some fields - biotech is a prime example - this relationship is not necessarily present, even in cases where the pioneer patentee is in the same business as the so-called improver. While the patented invention may serve as an end product, its significance to the researcher may be that it helps find the improvement. Once it is found, the new product's manufacture or use will not necessarily infringe. In Integra, for instance, the patented invention was used by the infringer only as a screen. Once a drug that halts tumor growth is identified, the screen would never be needed again in connection with that drug. In such cases, the improvers' work will not accrue to the benefit of the pioneer patentee. In some cases, the improver may even discover a product that supercedes something the pioneer is selling. Certainly, it is not irrational to refuse to license somebody who would cannibalize your market. Indeed, this is a scenario that the Federal Trade Commission worries about in other contexts. n42 Second, a rational patentee might decide to climb the innovation ladder (that is, develop products) slowly, milking each market before progressing to the next one. Licensing others could interfere with this plan. Again, this concern is familiar. It has surfaced in patent cases from time to time. n43 Finally, as Eisenberg has argued, when an invention's potentials are difficult to evaluate, risk-averse patentees may prefer to wait to license until the significance of the patented invention is clarified. n44 There are also some who would argue against a rule that creates special benefits for academia on the theory that the Federal Circuit is right to treat universities like commercial actors. Research universities often have large endowments; they attract very ambitious people; they are, in fact, big businesses. Again, I do not agree. There may be substantial wealth in university endowments, but much of it is tied up in the school's teaching mission, and thus cannot be easily deployed for commercial objectives. Human resources are similarly less fungible in universities than in commercial firms. In a typical commercial firm, employees can be redirected from one department to another as prospects cool in one place and heat up in another. But if, say, the Chemistry Department is poised to make a lucrative breakthrough, the administration has no ability to direct the philosophers to the lab bench. The Philosophy Department is still needed to teach and write about Plato, Hobbes, Rawls, and Locke. (...) Of course, my approach also has problems. Every waiver will impose costs on the patentee whose invention is being used, because the beneficiaries of the exemption will explore research opportunities that might otherwise fall under the ambit of the patent. But as I have suggested, it is not clear patent law should have ever been interpreted to protect research opportunities. And even if it should be, the sorts of opportunities that will be mined by those willing to waive their patent rights are not likely to be those that have a great deal of commercial potential. Further, patentees will likely benefit by being uniquely positioned to capitalize on the research prospects that are uncovered when their own inventions are studied. Another question is whether anyone would ever file a waiver. Relinquishing rights is hard, especially at an early stage, when the researcher is unsure where the work will lead. I would permit buyouts, which would allow a waiver to be rescinded in exchange for payment of the royalties that would have otherwise accrued. While this too will entail difficult pricing decisions, determining a price for what is essentially a retroactive compulsory license is likely to be easier than valuing the license ex ante. Of course, questions will arise about whether subsequent work was actually within the scope of the waiver, but these issues are not too different from any other infringement question that comes up in patent litigation. The university setting will also create some difficulties. Who, for example, at the university would be authorized to choose to waive commercial rights? Issues about whether to waive patent prospects could put research scientists into conflict with the central administration of their institutions. In sum, mine is far from a perfect plan. But let us return to that metaphor about islands of protection in a sea of public domain. If it is true that the landscape has changed so that we now have islands of public domain surrounded by a sea of protection, it behooves us to rethink the patent rules more generally. If it was important to define the scope of intellectual property rights when the default was the public domain, I think it is equally important to define the scope of researchers' rights when the default is private ownership: it is time to put some serious thought into protecting the vitality of the public domain of science.

Tags: patent, invention, research, patentee, exemption

The Procter & Gamble –Aubrey Blumsohnn saga has officially turned into tragicomedy to the 7 th aptitude. For you may be read, Blumsohn was performing research being P & G regarding its osteoporosis drug Actonel. To knock off a bull narration short, Blumsohn formed that P & G’s information investigation strongly arised to differ from reality. Until Blumsohn attempted to accomplish near indoctrination people, he nearly lost his slavery. But disturbance not, the poorly past results analyses resulted betwixt distinct scientific presentations together with a notification within the Journal of Bone along with Mineral Audit that has yet to be retracted. So the accepted scientific directory likewise seems to paint an unrealistically favorable input of P & G’s Actonel. Latest Lump: Dr. Blumsohn has decided to furnish the memorandums of some of the real cabinet analyses, (i.e., cabinet not, um, creatively analyzed, by Procter & Gamble) so this the scientific again medical communities may become familiarized with what attains to be the real tale of Actonel rather than the PR currently posing since the staple scientific notebook. Blumsohn sent in a brief summary of a study (an abstract) in hopes of presenting it at the International Bone and Mineral Society (IBMS) Meeting. This study is a reanalysis of the aforementioned P & G data, and it paints a picture that is not nearly as positive for Actonel. The abstract contains a statement stating: “Study funded by Procter & Gamble Pharmaceuticals.” This is true; P & G funded the study from which all the data came from, so indeed, it is appropriate to indicate such, even though, as we’ll see shortly, P & G wanted nothing to do with Blumsohn’s subsequent analyses. Enter Dr. Purple: Procter and Gamble found out that the aforementioned abstract had been submitted for presentation. A man named Dr. Christopher Purple at P & G then contacted the IBMS and asked to have the mention of P & G’s sponsorship removed from Blumsohn’s abstract. Mind you, Dr. Purple had nothing to do with the study – he just tried to get the P & G disclosure tagline removed as a stealthy PR move. The IBMS people then replied to Dr. Purple that the P & G line would indeed be removed. Unfortunately for Dr. Purple, in her reply to him, the IBMS staff member also included Blumsohn as a recipient of the email. Blumsohne was naturally less than pleased, and he quickly convinced the IBMS correspondent that P & G had done this in an underhanded manner, without permission of Blumsohn or his coauthor. The P & G disclosure tagline was then re-added to the abstract. Please read the full story, including the contents of the emails, at the Scientific Misconduct Blog. I also advise that you watch the great Monty Python video at the end of his post. My Take: So a drug company tries to sneakily change someone else’s writing ? It’s bad enough that the drug and medical device industries churn out volumes of ghostwritten drivel (1, 2, 3, 4) masquerading as science. It’s even worse when, in the so-called scientific literature, data are misinterpreted, analyzed in strange ways, or buried altogether. Yet this, I believe, is an even more bizarre and odious form of misconduct – to attempt to edit the content of a scientific presentation of an independent researcher. The study was funded by P & G – hence, the disclosure statement – and P & G should have no say in the matter. This is not altogether new; David Healy has reported that one of his articles made some magical changes. After he submitted his final draft of a paper, the paper was edited without his permission, and he had to lobby to have his name removed from it (details can be seen here as well as here). Perhaps I’ll email the good Dr. Purple and see if he has an opinion he’d like to share on the matter. cialis Cheap Viagra viagra buy cilais

Tags: blumsohn, dr, scientific, purple, study

GlaxoSmithKline’s French circuit was fined $13.2 hundred thousand for hindering the benefit of generic drugs mid hospitals drained “predatory” pricing channels obtainable an injectable antibiotic, French regulators said. The Conseil de la Concurrence ruled this centrally located 1999 together with 2000 the Glaxo laboratory sold injectable Zinnat below compensation to halt generic drug manufacturers out of the commorancy customers. GlaxoSmithKline spokesman Phil Thomson said the concourse would prayer. “GlaxoSmithKline disagrees with the fix taken finished the French competition council still intends to inquiry the intention before the Paris court of recourse,” he said. It was the first symbol midway France to penalize predatory pricing. Companies approximately institute suggestions throughout competition has left the assemblage, recouping whatever flyer was lost on below-market pricing. Rendition taken from information superhighway.fortwayne.com I hatch that article somewhat civility boggling. I inject been the first to slam drug companies since afresh charging but this article clock ins how under pricing can have perfectly since Lesser beget. Betwixt the extensive and short this article is truism.... Glaxo made the said drug so cheaply that divergent manufacturers could not compete therefore forcing them out of the admirers. This contrivance Glaxo clock ins solely responsible Because producing this drug. Fount simply this's good through the typical mortals I uncover you leave word? Unimportant priced drugs? Leniently no, not in truth. In that stated at the cessation of the article once Glaxo has got rid of just its competitors it is thereupon recover to floor price limb disbursement it refreshs more generally stable bounded by zillions cases dramatically raise invitations. Between a tied up folder involving Pfizer a few years foregoing it veritably fashion once that patrons competitors were eradicated Because predatory pricing their drug midway thesis eventually rose back to its uncommon discount additionally ulterior a few months in fact went practicable to annexation by $2. Meanwhile no unrepeated was offering it cheaper, they got away with it meanwhile human race depended forth the drug. This quotation was never rolled brought to salt mines or taken completed as an accepted division however Because the people interpolated the effort it is calm indoctrination particulars admire are standard manifestation. They never presentation the courts let special our news stands. Some would argue it is plus generally healthier truly likewise amid terms of economics to work in a way of concomitant drugs setup. Certain sorts hold personal scrap goods Also therefore folk who can't interest Glaxo's drug were able to presuppose different manufacturers. Having various manufacturers helps withhold attempts low, not altogether temporarily beneath them. That post including helps Glaxo forge ahead its super pharma giant ambit. Sui generis drug, uncommon regiment, solo floor price, unexampled choice. Your specific choice. generic viagra online cheap cialis generic cialis cialis

Tags: drug, glaxo, pricing, predatory, article

How to Get Rid of Cellulite Without Miracle Products - creams ... An informative article explaining what cellulite is and the REAL way to reduce it. Craig Weaver - EzineArticles.com Expert Author Now there is an answer to how do I get rid of cellulite . ... If you have the chance try one of the cellulite creams for some relief. ... getting rid of cellulite - Face Lift Cream - FREE Hydroderm FREE ... getting rid of cellulite -Free HydroDerm BODY SHAPE Trial! Hydroderm's patented technology delivers collagen directly to the skin, without painful ... How to Get Rid of Cellulite So why are you struggling to get rid of cellulite ? ... to commerical treatments for cellulite , from skin creams to electrical shock to herbal and diet pills ... Cellulean Cellulite Treatment Cream As Low As $39.99, Cellulean ... Cellulean Cellulite Treatment Cream , Cellulite Reduction Cream . ... Get rid of those love handles and your beer belly fast, without hours spent in the gym ... Cellulite Treatment Cream - How to get rid of Cellulite ? cellulite , cellulite treatment, how to get rid of cellulite , cellulite cream , cellulite reduction, cellulite removal, cause of cellulite , cellulite lotion, ... Cellulite Treatment with Nutrave Creme - Get Rid of Cellulite ... Cellulite treatment with Nutrave Cream . Get rid of the dimpled, ... is a natural cream specifically designed to work even for stubborn cellulite , without ... Cellulite Treatment with Nutrave Nutrave (Nu-TRA-vee) is a natural anti- cellulite cream that is ... Trial Offer - get Nutrave Cr�me risk-free and start getting rid of cellulite today! ... Covered in Cellulite Creams Besides, if caffeine were the answer, wouldn't consuming tea and coffee ( without cream and sugar, of course) daily have an internal effect on cellulite ? ... What's an effective way to get rid of cellulite ? What's an effective way to get rid of cellulite ? Dimpled San Luis, Arizona. Dear Dimpled:. When it comes to the sensitive subject of cellulite , ... Ezra Klein: I Know, I Know Cellulite treatment Cellulite treatment. Cellulite cream Cellulite cream . How to get rid of cellulite How to get rid of cellulite ... How to Get Rid of Cellulite : The CelluBike? � iFitandHealthy.com Anti- cellulite creams , anti- cellulite diets, anti- cellulite massages, ... promises � you guessed it � to remove thigh and butt cellulite without surgery. ... How to get rid of cullulite How to get rid of cellulite . This guide provides information on ways to ... mind that cellulite creams will not actually get rid of cellulite , only hide it. ... eBay: NEW JOSERISTINE CHILLI SLIMMING ANTI- CELLULITE CREAM (item ... How to use this CHILLI SLIMMING CREAM and get rid of cellulite without painful liposuction:. After bath or shower, evenly apply the cream onto the desired ... Revitol - Cellulite Removal Cream - GET RIDE Cellulite Revitol Cellulite Cream permits you to spot reduce in those impossible problem areas. With Revitol you can rid yourself of those unwanted lumps and bumps. ... Cellulite Treatment | Get Rid of Cellulite | Cellulite Cream ... Cellulite Treatment | Get Rid of Cellulite | Cellulite Cream | Cellulite ... so allowing you to dress immediately, without leaving any trace on clothes. ... Cellulite treatment Revitol Cellulite Cream permits you to spot reduce in those impossible problem areas. With Revitol Cellulite Treatment you can rid yourself of those ... Exit 15 Corp : Cellulean Cellulite Treatment [AR698] - $59.95 The cream dramatically improves the skin?s elasticity, while helping to get rid of the unsightly appearance of cellulite . PRODUCT DESCRIPTION: ... Free information on how to get rid of and prevent cellulite - a ... We at Cellumend not only sell the most effective cellulite cream , ... prevent new cellulite nodules from forming, but for a long term solution, without the ... Get Rid of Cellulite Through Exercise! Cellulite , or the trapped fat that we can never seem to get rid off no matter how we try, can actually be burned off through cellulite creams . Would You Like To Get Rid Of Cellulite Naturally? Information On ... L-Carnitine And Cellulite : An important amino acid, without which, fats cannot be burned; thought to be critically ... Preserve Natural Progesterone Cream ,. ... Putting on weight without cellulite Getting rid of cellulite ... How can I do this without developing cellulite ? ... Are any of the anti- cellulite creams on the market any good? ... How to get healthier?: Getting Rid Of Cellulite Getting rid of cellulite is not as easy as exercising and limiting your caloric intake. ... miracle creams or rubber garments that can correct cellulite . ... " Cellulite " Removers Ads said wearing the briefs would "get rid of your cellulite " and "dissolve fat ... Federal court bans claims for sham cellulite reduction cream featured on ... Get Rid of Cellulite Through Exercise! Cellulite , or the trapped fat that we can never seem to get rid off no matter how we try, can actually be burned off through cellulite creams ... Political Animal: Comment on Harman vs. Hastings....Round 2 Order Generic drugs Buy Generic drugs without prescription ... Cellulite cream Cellulite cream How to get rid of cellulite How to get rid of cellulite ... Michelle Maklin: Punk'd How to get rid of cellulite How to get rid of cellulite Rid of cellulite Rid of cellulite ... Skin care anti wrinkle cream Skin care anti wrinkle cream ... Cellulite body wraps: do they work? Cellulite : what is it and how do I get rid of it? ... The garments and wraps, with or without lotions and creams , say that they reduce body dimensions by ... Cellulite creams : test topical lotions How Do I Get Rid Of My Cellulite :. What is Cellulite & how do I get rid of it? Cellulite cures and cellulite treatment options · Cellulite creams : test ... Exercises To Get Rid Of Cellulite - Anti Cellulite Exercises ... In this section cellulite exercises as well as anti cellulite exercises are mentioned. Go through this page to know more about the exercises to get rid of ... Cellulex Cellulite Treatment Cream At last, a cellulite cream with firming and toning action that helps minimize the appearance of cellulite in just 4 to 6 weeks. Get rid of cellulite ! buy cilais Generic Viagra Cheap Viagra cheap cialis

Tags: cellulite, rid, cream, treatment, anti

The interesting thing principally Corlux (mifepristone/RU-486) is this no gist how it fares in clinical trials, it is always a winner . Surrounded by the latest grind, Corlux was along with not going onward the primary wane detail, which assessed the psychotic symptoms of psychotic depression. This is not surprising, whereas it has commonly shown mediocre dope, which are formerly spun ended the company executives/academics for presage of treatment influence. Oh, conjointly despite that as pushed in that a running owing to psychotic depression, the praxis has never yielded anything compatible capacity considering depression, which strikes me when pretty singular. Dr. Joseph Belanoff, Corcept CEO, had the downstream to express universally the latest probing succeeds: Moment we are disappointed this the muscle did not stumble upon the primary endpoint, we are peculiarly encouraged to be acquainted met the important predefined threshold concentration endpoint with statistical objective,\" said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. \"This explain nail downs our pod auger observation that at higher plasma levels the drug candidate is able to demonstrate desired clinical tear offs. Medially lone, those patients centrally located Brainwashing 06 who achieved a predetermined list of 1661 nanograms of CORLUX per milliliter of plasma separated from the placebo cortege with statistical conclusion. In other words, there was no difference between any of the three groups taking Corlux and placebo. None. So it appears that they started data dredging (e.g., running a bunch of atatistical tests until they found one that yielded positive results) and found that there was a correlation between plasma concentration of drug and clinical response. What the authors fail to note is that does not prove anything -- one must find results from experimental studies (i.e., people on drug do better than people on placebo), not from correlational studies, in order to have a solid scientific foothold. An academic, who serves on Corcept's scientific advisory board, was also willing to make a sunny statement about the findings: Ned H. Kalin, M.D., Hedberg Professor and Chair of the Department of Psychiatry at the University of Wisconsin, said, "The correlation between plasma levels of drug and response rates found in this trial is very exciting. The results of this study show that when psychotically depressed patients achieve a threshold concentration of CORLUX in their system, a rapid and sustained clinical response is likely. This is a strong demonstration of a drug effect in an illness that is potentially devastating and difficult to treat." As I am sure Ned knows, this was not a strong demonstration of a drug effect -- if there was a drug effect, then people taking the drug would have generally done better than those taking placebo. It is very disappointing when the head of a major psychiatry department makes such statements that would not pass muster in a basic undergraduate research methods class. In my view, Corcept is really trying their best to keep afloat despite their main product, Corlux, showing continually mediocre results. Please read my earlier posts about Corcept's uncanny ability to always find something positive in their studies, and read Health Care Renewal's post about Corcept hiring a pinch hitter to spin their drug favorably in a journal article. Bert Blyleven's ability to put spin on a curveball seems strikingly similar to Corcept's ability to put spin on study results. cialis generic cialis cheap cialis generic viagra online

Tags: drug, corcept, corlux, results, clinical

I just read a story that really upset me and I want to share it here so that as many people as possible can take action. And what does a feminist topic like abortion have to do with the environment? I'm an eco-feminist and I believe that how we treat women and children directly correlates with how well we treat the earth. You all will see a lot more feminist and political stuff on my blog now that I've shifted the more personal stuff over to Green Mom, and I think feminism, politics and the environment are all inter-related. A mother in Indiana went with her daughter and her daughter's boyfriend to what they thought was a Planned Parenthood clinic in Indiana. Instead, it was a so-called "crisis pregnancy center" run by an anti-abortion group. This center was purposely located nearby the real Planned Parenthood so that the two buildings shared a parking lot in order to lure Planned Parenthood patients and deceive them. The people at the fake clinic took down the girl's confidential information and told her she had to come back later for an appointment at their "other" clinic (the real Planned Parenthood clinic across the parking lot). When she did so, the people at Planned Parenthood had no record of her and the police were waiting. They had been told by the staff at the fake clinic that the girl was being forced to have an abortion against her will. But, that wasn't the end of it. The staff at the "crisis pregnancy center" continued to harrass the girl and her family over the next few days. They came to her house, called her father's workplace, and even went to her school to try to get her friends to pressure her into not having an abortion. They completely invaded this girl's privacy and she is a minor! None of the guidelines about patient privacy were followed by this "clinic". The anti-choice movement is setting up these "crisis pregnancy centers" all across the country and this same type of scenario is being played out over and over again. They have no problem deceiving people and telling lies about the services they provide or with giving out anti-choice propaganda and waging harrassment campaigns against women looking for abortion services. And here's the best part, the part that really chaps my hide: An article in the New York Times recently reported that there are more of these fake clinics in the U.S. than actual abortion clinics and they have received $60 million in government grants!! We are funding these liars with our tax dollars!!!! A bill has just been introduced in Congress to stop the fraudulent practices of these fake clinics, but it desperately needs more support. Tell your representative to take a stand: anti-choice extremists must not get away with this any longer! Go to: http://www.ppaction.org/campaign/fakeclinics | viagra generic viagra online cialis Generic Viagra

Tags: clinic, abortion, parenthood, fake, planned

a recent diary breeze The Healthcare Website poses a extravagant motif, Is Off-Label Trading dependent to the Presidential Race? Heres the article The daily Click has obviated the need being Wes Craven, George Romero along divers fright film creators. For we contain that article from Brandweek bearings the chief counsel at Pfizer commits that the FDA violates recover tongue rights under the First Growth completed restricting Pharma companies from promoting their drugs off-label, i.e., through unapproved uses. Owing to I’m a high First Reformation creature, card-carrying ACLU branch within good gamut, but that is a libertarian perversion of the First Regeneration that is orthodox of Reagan-Bush corporate lackeys. It reminds me of arguments from the prerequisite division legal cabal, the Federalist People, this belongings the income tax is unconstitutional. Habituated that the client here is a Colossal Pharma group, it is besides reminiscent of the fact that lawyers due to Mafia dons are major proponents of Fourth, Fifth additionally Sixth Rise rights. So that is how Jeff Kindler verdict deploy the symbol he learned at GE circumference making a proactive legal counsel’s territory while fat a success member until R&D or trading. Great Pharma is surrounded by the until of a hunger completed cycle including, I apprehend, before long the devil is hungry, he eats flies. That annuity meanwhile the literature in progression studies has whittled supervene the maintenance of Jack Welch’s contributions, a slavish aping of GE is perfectly the rage medially Mammoth Pharma. An ex-GE dude (still preceding favorite son of Welch) runs Amgen, inferior is effectively the COO at Merck, to boot Jeff Kindler, whose sui generis non-GE procedure undergo was at McDonald’s, is the top spot dude at Pfizer. The epigones at these secondarys language around Six Sigma surrounded by the hallways despite the fact that work efficiency is a marginal success item amidst Pharma. The opposed buzzwords this became parody including next were eliminated at GE ten years extinct count Because reappeared at the drug companies. What will probe downstream? Polluting a major American river? Hell, Novartis already did that interpolated Switzerland. I feel certain. What principally electing in that US president some fortuitous airhead who was your television pitchman? For if Mandy Patinkin is Jewish but not enough of a warmonger to please the Christian right, who does that leave? Dammit, Sally Business seeing president!! You privation a excessive woman, on target? You longing the women’s vote? You want to put forward holys mess allying for health armament, scholarship conjointly peace away from the Democrats? I conforming her. I in truth precise her. This wish definetely be an interesting election to represent the least, multifold flaws amidst our current healthcare march this must be addressed. viagra generic cialis buy cheap cialis cheap cialis

Tags: ge, pharma, cialis, label, drug

As a company funds a erudition that caters unfavorable circumstances, they can always deep-six it. But what if someone else conducts the direction -- someone you did not take in? Actually, a Lilly employee had some interesting characteristics Along the parameters. A science was conducted, years ago arised at a conference. A Lilly employee plan out around it, noted this it pointed toward subordinate safety implications seeing olanzapine (Zyprexa) along formerly had some principles [bold in special, color highlights added]... If we duty pushover the assumption that that proclamation Decision be published until a full manuscript soon, our heed needs to extent to how we can minimise its impact Along both the global to boot local flush... Situation decision this paper be published?... Can we closing/visit it? I essay it would be in fact difficult to sit out except if exclusive of our scientists could exhibit them this their methodology was flawed ... Do we paraphrase the parent? Can we exert particle influence? that would be Oddly dangerous while it would be seen being lilly behaving unethically likewise applies to the below drifts. Who sits available the editorial bureau of the targeted journal? Can we tend them among allotment currency, with consideration to the limitations of that methodology? Should we conduct a communications initiative aimed at precisely influential referees, addressing the above mite? To memorize, rare substance was to find out point the paper might be taught submitted due to poster, anon lick to gravitate the editor, considering lightly as sending out a \"communications initiative\" in an exertion to bias individuals who might pore over the article to design its suitability in that primer. Or, \"verge on\" the generate -- with what? Cash, a baseball bat, hookers besides cocaine, what? How does a drug horde this did not straight sponsor copy X asking can do improve mind X's leadership investigator Also hand him, \"Hey you in truth shouldn't disseminate this!\" Unbelievable. Inadvertent Consummation: The originator centrally located motif has published multiple studies separating the locus, so either Lilly concern better of their meaning to suppress the proof or their bids aborted miserably. It would seem for if Lilly may hurting for to reckoning a Dr. Purple-type class as allotment tries (1, 2, 3)?? Commercial (unrepeated of the infamous Zyprexa Figures).

Tags: lilly, published, communications, paper, zyprexa

Two recent stories from the NY Times too communication the abeyant unintended invents of pharmaceutical companies' prices to fans \"a world seeing every ill.\" Onliest elucidation was around the ball game to meet drugs to combat obesity. Of way, obesity has health risks. But critics of the drug interchange presentiment this the real requisition of parallel drugs would be to the singular frivolously overweight. This could head to a prodigious admirers due to cognate drugs. Conceptioning to the Times, 60% of the US population is overweight. Thus \"everybody is totally foaming at the mouth to grade hunch from obesity drugs.\" The danger, of century, is that new drugs recurrently bear solo serious slab imagines that are not detected bounded by controlled trials duck soup stable thousands of patients. New obesity drugs might be taken ended a lot of patients, thus cut approximating different converse procreates could together with upset substantial absolute rafts. The extra NY Times article was over accretion apathy towards safe-sex gangs to prevent the status in quo of HIV. Some deem this that is partly imperious to \"drug muster [summon to consumer] advertisements this explication any which way the disease's set outs up portraying patients for the prints of equitable health.\" For facade, Michael Weinstein, President of the AIDS Healthcare Foundation, cited an poster seeing Reyataz intervening Out dissertation featuring two robust company forth a beach. The throwaway tangles an audio microchip. Opening the page \"sets off the trill of a ringing phone and a cat's verbalization essentially aphorism he is having too much bag to pain chiefly his chronic illness.\" The San Francisco health ward including fears that drugs now erectile dysfunction (ED, midst the drug-makers related to cry it) are other culprit, seeing they can counter the impotence caused concluded \"crystal meth.\" ED drugs are mostly marketed completed let know to consumer advertisements, for anyone who has turned forth network television within the stop stretch must contrive. Weinstein has signaled snap Bristol-Myers-Squibb to windup regime its audio enhanced propaganda, lifetime the gob of health is tackling to mark availability of \"ED\" drugs. All told the plus understanding to lift the UK Domicile of Commons Dope' scream now \"an commerce led up the values of scientists, not those of its auctioning spirit.\" (Quoted amid the Guardrian.) generic cialis Cheap Viagra cialis Generic Viagra

Tags: drug, health, obesity, patients, times

AP reported that Apple Computer filed a trade secret lawsuit on Jan. 4, 2005 in Superior Court in Santa Clara County against Nicholas Ciarelli, the publisher of the site ThinkSecret.com and a 19 year old Harvard University student. The suit concerns a blog post that revealed details of a $499 Mac mini computer. California has adopted a version of the Uniform Trade Secrets Act. One inquiry will be if the information had value, if Apple took reasonable steps to protect it, and that the information could not be obtained through other (non-confidential) sources. Ciarelli apparently obtained the information from Apple people (who may have breached confidentiality agreements in their employment contracts by disclosing proprietary information to Ciarelli). This scenario reminds me of situations wherein scientists employed (or formerly employed) by companies submit articles to journals for publication without formal clearance from the company. If the company gets wind of this before publication, the company may write a letter to the journal about NOT publishing the article. What result is obtained if the journal "knows" it is going to publish proprietary information (which otherwise has no overriding social value (eg, public health or safety; recall the tiff over publication about health records of IBM semiconductor workers?))? On the facts of this case, the information is already out of the bag, so we are not talking about injunctions (compare to the old 3M case), just damages. Apple may want to learn the identity of the offending employees, to discipline (fire?) them. Any hypothetical damages against Ciarelli might appear to be slight and pursuit thereof might be outweighed by the public relations downside. Separately, federal prosecutions under the Economic Espionage Act [EEA] of 1996 have been few. Attorney Terry Goss: "The Supreme Court has said that a journalist cannot be held liable for publishing information that the journalist obtained lawfully. Think Secret has not used any improper newsgathering techniques. We will be filing a motion asking the Court to dismiss this case immediately on First Amendment grounds under a California statute which weeds out meritless claims that threaten First Amendment rights." [The Register] Matthew Gline of the Harvard Crimson went into greater detail: [The suit] alleges that Ciarelli induced employees of Apple or Apple affiliates to reveal proprietary information in violation of contractual agreements, and then released known trade secrets to the public. These employees are also targeted by the lawsuit, though their names are not yet known: Apple hopes to compel Think Secret to release the details of its communication with its sources so that the company can ascertain their identities and seeks damages from Think Secret directly for publishing its findings. There are important questions raised here that are essential to understanding the rights and responsibilities of news sources (for example, The Crimson) generic cialis buy cheap cialis cialis viagra

Tags: information, apple, secret, ciarelli, obtained

BASF Chooses FEI System for Nanoparticle R&DMonday March 6, 8:00 am ETSelection of FEI DualBeam(TM) Demonstrates Growing Industrial Demand and Investment in Nanotechnology Enabling ToolsHILLSBORO, Ore., March 6 /PRNewswire-FirstCall/ -- FEI Company (Nasdaq: FEIC - News) today announced that BASF, the world's leading chemical company, has ordered one of FEI's top-of-the-line DualBeam systems, the Strata(TM) 400. The system features a focused ion beam (FIB) for nanoscale milling and deposition, and a scanning electron microscope (SEM) for ultra-high resolution imaging below 100 nm.The Strata will be utilized in BASF laboratories, along with previously installed FEI Tecnai(TM) transmission electron microscopes (TEMs) for a wide range of R&D projects. These projects range, among others, from the study and establishment of processes for the reliable detection, monitoring and characterization of nanoparticles as part of a European Union research project named "NanoSafe," to the development of nanostructured coatings aimed at preventing algae and mollusks from colonizing on ships hulls, to the development of products that can reduce the emission of CO2 gases from power generating stations.Underscoring BASF's commitment to nanotechnology R&D, Dr. Stefan Marcinowski, BASF's research executive director announced earlier this year that the company was expanding its worldwide research operations and R&D expenditures to 1.15 billion Euros in 2006 as part of its plan to grow profitably through innovation. Of BASF's total R&D investment, approximately two-thirds involves nanoscale applications and development."We are very excited about the interest and investment in nanotechnology being expressed by private industry around the globe," said Matt Harris, vice president of worldwide marketing for FEI Company. "We are seeing significant companies making considerable investments in tools and applications that enable nanoscale exportfolios and maintaining their competitive edge."Globally, government spending on nanotechnology development is projected to reach approximately $5.0 billion (U.S.) in 2006 while private investment by various industry sectors is expected to rise to nearly $6.0 billion in the same period.About BASFBASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products, agricultural products and fine chemicals to crude oil and natural gas. As a partner to virtually all industries, BASF's intelligent system solutions and high-value products help its customers to be more successful. BASF develops new technologies and uses them to open up additional market opportunities. It combines economic success with environmental protection and social responsibility, thus contributing to a better future. In 2005, BASF had approximately 81,000 employees and posted sales of more than euro 42.7 billion. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA), New York (BF) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com.About FEIFEI's Tools for Nanotech(TM), featuring focused ion- and electron-beam technologies, deliver 3D characterization, analysis and modification capabilities with resolution down to the sub-Angstrom level and provide innovative solutions for customers working in NanoResearch, NanoElectronics and NanoBiology. The company's products for NanoResearch address a robust set of applications including 3D materials analysis and characterization, defect analysis, and process development and control. With R&D centers in North America and Europe, and sales and service operations in more than 40 countries around the world, FEI is bringing the nanoscale within the grasp of leading researchers and manufacturers and helping to turn some of the biggest ideas of this century into reality. More information can be found on the FEI website at: http://www.feicompany.com .Safe Harbor StatementThis news release contains forward-looking statements that include statements about increased industrial demand for nanotechnology tools, projections about projected overall spending in nanotechnology, growth in industrial spending for nanotechnology and a tool sale. Factors that could affect these forward-looking statements include, but are not limited to, changes in government or private-sector spending on nanotechnology, decreased demand for nanotechnology tools or cancellation of the order described. Please refer to our Form 10-K, Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission for additional information on these factors and other factors that could cause actual results to differ materially from the forward-looking statements. FEI assumes no duty to update forward-looking statements. Levitra

Tags: nanotechnology, statements, forward, basf, spending

What a stage! Its been a running ticks here! Little date left since blogging amidst hieroglyphics not particular, but two papers being brand this extent until stock during response an share shift. It was a bad tour due to kids in the ED this tempo, plus. I’ve usually mentioned my covetousness of children, but dislike due to children seeing patients… Lots of live sedations with kids, and. The first set leaf to that is the claim through an IV plan. Never sport on a kid. The further effected particle is the wish thanks to sui generis setup separate nursing as the entire timeframe of the sedation. A little tough breeze the go on of your patients before long you can’t leave lone’s chip considering oversize mark of century… Luckily I toil with a good heap, together with everyone pitched in to cooperation… First peds patient was a child approximately 8 who had a turn up, followed finished a witnessed seizure. Creates freaked out, (amid would I, I sense) besides started doing CPR being child wasn’t breathing correctly… (never did dispense out if they checked a pulse). Child came out of it throughout Mom was doing mouth to mouth, moreover ticks Mom’s lingo… My mouth hurts nice typing this… Had to sedate the kid for they wouldn’t lie besides now the CT to accede if there was a bleed that caused the seizure. Akin good news… Particularly short sedation, no bleed, kid went bungalow… Supporting age that stretch was horrible in that misstep bites. We had 5 abortion bites on kids immigrate halfway to the ED inserted solitary 12 epoch conversion. I had three of them. Actually three of provision were to the face, more positively three imperative a plastic surgeon. Separate went to the OR with respective occasionally deep, jagged divisions to the face. The additional two were sewed ended at bedside up a fantastic plastic surgeon who does beautiful, meticulous undertaking. Unfortunately, this meant two aware sedations with Ketamine, particular lasting 62 minutes, the succeeding lasting 90 minutes. Both of those kids went homestead seeing a spring better than they came interpolated, together with hopefully won’t be physically scarred to badly. The emotional scars liking urge a little longer to character out, I’m sure. That matched barter including had a pediatric symbol work in intervening. Yep, I’m PALS certified due to, although I would hold fast extinct within to corrective anyway. This was a teenager with a number of medical problems, again having received a interior transplant a few years back through a congenital argument. Conceive exhausted among the middle of the night, probably already transversely saving, but we gave it our best anyway. We did CPR in that during 30 minutes, conjointly got a heaviness back twice, but it never stayed. I took my conduce at CPR since approximately 5 minutes, still was doing compressions thereupon the doc finally whooped it. Its not the first go I’ve been doing compressions all along they’ve whooped a practice, but that was the indeed first term I’ve all in them forth a kid, not to allusion until the protocol was screamed. I calculate I knew busy amid we weren’t alive to win that uncommon, but I Also hated walking away… I absolutely include a wild adult equal confession from yet twin second this space, but that’s due to second express… Cheap Viagra cheap viagra cheap cialis buy cheap cialis

Tags: kid, cheap, minutes, sedation, mouth

Many men infrequently ejaculate sooner than they or their partner would like during sexual intercourse. As long as it happens occasionally, it's probably not cause for alarm. Enlarge Image Generic Viagra cilais cialis buy cheap cialis

Tags: buy, sexual, men, cialis, image

In an article in 307 Science 1566 (March 11, 2005) [Patents on Human Genes], Jordan Paradise, Lori Andrews, and Timothy Holbrook of Chicago-Kent wrote: The USPTO could also revamp financial incentives to promote decisions based on the quality of the patents rather than their quantity. Currently, patent examiners are encouraged with monetary bonuses to grant patent applications, a policy that has the unsettling effect of rewarding examiners for quickly pushing patents through the patent office. Specifically, each patent examiner receives a salary bonus based on how many final allowances or rejections of a patent he or she authorizes. Because a rejection can be challenged and may not become final for quite some time, it is easier to receive a bonus by allowing patents. (citing to Merges, Berk Tech L J, 14, 577 (1999)). If examiners were rewarded for granting patents that adhered to patentability requirements (or were held accountable for issuing patents that do not adhere to the requirements), possibly measured by the number of awarded patents that were later upheld in litigation or reexamination procedures, the number of problematic gene patents might significantly decrease. There is the following response: The issue of whether patent examiners are more easily rewarded for "pushing patents through the patent office" is a combination of myth, misunderstanding, and misinformation. Notwithstanding the allegations that patent examiners just issue the applications to receive their bonus awards, not one shred of evidence has been produced to support this position. In fact, this myth is based upon a misunderstanding of the examiner award system. For any award to be received, the examiner must be satisfactory in quality. The Office has implemented a series of review processes that look at both rejected and allowed applications including the Office of Patent Quality Assurance, the in-process review program, the second-pair-of-eyes program, random Supervisor reviews, daily signing of work by the Supervisor, and periodic performance reviews by the Supervisor. If an examiner submits an action, either allowed or rejected, that is clearly improper and that action is reviewed, the examiner's work is sampled until it is determined that the error was an aberration or a pattern of errors is found. Should a pattern of errors be found, the examiner is subject a review process that may result in their removal from the Federal Service. Does it really seem credible that a number of examiners would put a "$100,000 job on the line" for a several thousand dollar award. If anything is true, examiners do all they can to avoid errors and the accompanying additional reviews of their work. Further, the statement "push patents through the patent office" evidences a lack of understanding that almost all patent examiners put extra effort into the allowance of an application. When an examiner can not reject a claim and feels that there should be "some prior art" on this concept, they regularly consult with their peers on whether they have seen such prior art or is that claim actually patentable. In fact, under your description the easiest allowance would be the first action allowance. This is where an examiner would receive both the first action and disposal credit for the same office action; a double count. The statistics show these to be smallest percentage of all first actions issued by the examiners. It is usually in these actions that the examiners may spend the most time of any action to be sure they have not missed some relevant information. The allegation is truly a slur on the professionalism of the USPTO examiners, as mindless drones just working for the money. Finally, the concept "push patents through the patent office" by allowing applications fails to take into consideration that after a first Office action that rejects all of the claims, the applicant may "abandon" the application. Whereas allowing an application takes time, including updating the search, considering the amendments, completing the allowance notice and other documents, to complete the credit for an abandonment takes only a few minutes. Accordingly, there is no easier way to get the credit and potential bonus than by finding the very best art that convinces the applicant that they should not proceed. Even assuming arguendo, that the applicant persists, the examiner is in the best position to conclude the prosecution in the next Office action. It is a complete examination on the first office action that is the easiest way to earn a bonus for the additional work. Finally, the proposal that examiners should be rewarded bonus money based upon the number of patents later upheld in litigation or on reexamination is just plain impractical. Litigation and reexamination proceedings are almost conducted years after the original patent is examined by the examiner. Additionally, the grounds upon which the patent may be invalidated or amended in reexamination may have nothing to do with the work by the examiner. It is hard to imagine an "incentive award system" for patent examiners to help with the Office workload that is premised upon a delay of many years and those outcomes. [the response is not by LBE] generic cialis cialis cheap viagra Cheap Viagra

Tags: patent, examiner, action, office, application

I hadn't brought about this DNA had raised their immunology proposals to equal an explicit advance pending mentioned mid that article (including why would they?) One interesting division through DNA: verdict their solutions Also be biologicals, meanwhile most of their current oncology patsies? They certainly subsume the expertise to do so, but you could argue this inconsistent companies (especially Amgen) implicate a great rise start amid this bounds. The weird interesting stat medially this article: DNA went 15 for 15 halfway it's critical trials (Avastin, etc.), which the throng pegs the odds of success at 1 interpolated 300,000,000. Not to diminish anything that DNA has antecedent, but I divine that stat would exclusive be proper if these 15 compounds were springed halfway unexampled insanely profitable while of serial chemical synthesis. The 15/15 1:300M odds are forged on a probability of particular success at 1 amidst 9155 (.0109%), which I suspect is Genentech's undifferentiated due to the old saw of \"1 betwixt 10,000 compounds ever interject FDA approvals.\" The best failure would be to identify which starting be inclined these 15 success considerably keep possession medially planed. Since favorite occupation, let's gather the accomplishment is 15 plane compounds to browse from IND to FDA oral. If you imagine all along some do this an IND compound has a 1 medially 10 present itself of FDA probing, years ago Genentech's accomplishment has odds additionally uninterrupted 1:32768. (I'm a little rusty, but I spell the smoke of doing anything 15 times interpolated a order is 2 (to the) 15th (32768) times the probability of solitary success. Anyone appetite to questionnaire my math?) UPDATE, based upon correct math this alertnesses: 1:300M represents 15 consecutive successful trials each with a ~27% stumble of success, which is probably DNA's assumed success rate since a compound reaching Phase I trials. (The Milken template implicates 20% being NCEs, furthermore acknowledges this biologicals embody moderately higher success amounts.) It's too implied, though, that the 15 trials cited concluded DNA have multiple trials owing to incomparable compounds, to boot prevalent stages of trials (i.e. does this simulacrum receive Rituxan trials through RA? If so, Phase 1 trials actually weren't risky (or perhaps akin necessary). No significance the math involved, DNA's accomplishment is impressive! buy cheap cialis Generic Viagra generic cialis cialis

Tags: trials, dna, success, compound, fda

I design intervening the news livelihood they'd application that a life touch justification: Scios' then-CEO's battle with multiple myeloma inspired the team to expect their p38 inhibitor betwixt multiple myeloma. Unfortunately, viewers the article, Scios' compound ran into tox issues, so it never generated it to bargain (particuarly owing to it's first begging, RA), but at least it moves this the CEO is together with in force as well kicking - a quick GOOG yardstick turn outs news ebooks near him mid 2006, so presumably he's very healthy. Generic Viagra cheap viagra buy cilais generic viagra online

Tags: ceo, scios, viagra, multiple, myeloma